Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology giant Ginkgo
With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell therapy, synthetic biology upstart Antheia is looking to aid in the fight. It just announced a deal with a giant in the field to help it along.
Antheia will join forces with Ginkgo Bioworks to beef up its pipeline of active pharmaceutical ingredients and key starting materials, leveraging Ginkgo’s high-throughput enzyme design and screening infrastructure to scale up at higher speed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.